Current Issue February 2012, Vol. 48, No. 3

Issue Highlights

Ulceration and stage are predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991
January 2012 (Vol. 48 | No. 2 | Pages 218-225)
Alexander M.M. Eggermont, Stefan Suciu, Alessandro Testori, Wim H. Kruit, Jeremy Marsden, Cornelis J. Punt, Mario Santinami, François Salès, Dirk Schadendorf, Poulam Patel, Reinhard Dummer, Caroline Robert, Ulrich Keilholz, Antoine Yver, Alan Spatz
Targeted agents: How to select the winners in preclinical and early clinical studies?
January 2012 (Vol. 48 | No. 2 | Pages 170-178)
Rachel Goodwin, Giuseppe Giaccone, Hilary Calvert, Marinus Lobbezoo, Elizabeth A. Eisenhauer
The efficacy of zoledronic acid in breast cancer adjuvant therapy: A meta-analysis of randomised controlled trials
January 2012 (Vol. 48 | No. 2 | Pages 187-195)
Tingting Yan, Wenjin Yin, Qiong Zhou, Liheng Zhou, Yiwei Jiang, Yueyao Du, Zhimin Shao, Jinsong Lu

EJC News Focus

WATCH VIDEO

The combination of targeted agents in hormone-sensitive breast cancer may be the way ahead; results from the CLEOPATRA and BOLERO-2 trials, presented at the recent San Antonio Breast Cancer Symposium (Dec 6-10, 2011), suggest that some combinations may dramatically increase progression-free survival.

Also at the meeting, several studies reported on the role of bisphosphonates in the adjuvant setting, which may resolve previous confusion about which women will benefit.

In this month's EJC News Focus, Rob Coleman (University of Sheffield, UK), who was at the meeting, discusses the implications of the new data with Helen Saul.

Reply to Professor Mercadante: Stop and go strategy for opioid switching requires flexibility
03 February 2012
Kristin Moksnes
To the Editor: We are grateful for the interest and response from Mercadante. This study was a randomized, phase II study, and we agree that there were obvious limitations, as discussed in the article...
Is the prognosis of stage 4s neuroblastoma in patients 12months of age and older really excellent?
03 February 2012
Tomoko Iehara, Eiso Hiyama, Tatsuro Tajiri, Akihiro Yoneda, Minoru Hamazaki, Masahiro Fukuzawa, Hajime Hosoi, Tohru Sugimoto, Tadashi Sawada
Abstract: Purpose: In the International Neuroblastoma Risk Group (INRG) classification system, stage 4s was changed into stage MS in children less than 18months of age. Stage MS is defined as a metast...
ERG protein expression reflects hormonal treatment response and is associated with Gleason score and prostate cancer specific mortality
03 February 2012
Tarek A. Bismar, Michael Dolph, Liang-Hong Teng, Shuhong Liu, Bryan Donnelly
Abstract: Background: ERG (ETSregulated gene) protein expression has been shown to reflect ERG genomic rearrangements in prostate cancer (PCA). However, ERG protein expression prognostic value has not...
Risk of haemorrhagic and ischaemic stroke in patients with cancer: A nationwide follow-up study from Sweden
01 February 2012
Bengt Zöller, Jianguang Ji, Jan Sundquist, Kristina Sundquist
Abstract: Background: Stroke is common in cancer patients, but risk estimates for different cancer sites/types have not been determined. The aim of this nationwide study was to examine whether there i...
Sham-controlled, randomised, feasibility trial of acupuncture for prevention of radiation-induced xerostomia among patients with nasopharyngeal carcinoma
30 January 2012
Zhiqiang Meng, M. Kay Garcia, Chaosu Hu, Joseph Chiang, Mark Chambers, David I. Rosenthal, Huiting Peng, Caijun Wu, Qi Zhao, Genming Zhao, Luming Liu, Amy Spelman, J. Lynn Palmer, Qi Wei, Lorenzo Cohen
Abstract: Background: Xerostomia (dry mouth) after head/neck radiation is a common problem among cancer patients. Quality of life (QOL) is impaired, and available treatments are of little benefit. Thi...

View More Articles in Press...

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
January 2011 (Vol. 47 | No. 1 | Pages 8-32)
M.S. Aapro, J. Bohlius, D.A. Cameron, Lissandra Dal Lago, J. Peter Donnelly, N. Kearney, G.H. Lyman, R. Pettengell, V.C. Tjan-Heijnen, J. Walewski, Damien C. Weber, C. Zielinski
A systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in metastatic colorectal cancer
June 2011 (Vol. 47 | No. 9 | Pages 1343-1354)
Barbara-Ann Adelstein, Timothy A. Dobbins, Carole A. Harris, Ian C. Marschner, Robyn L. Ward
New drugs in melanoma: It’s a whole new world
September 2011 (Vol. 47 | No. 14 | Pages 2150-2157)
Alexander M.M. Eggermont, Caroline Robert
Preoperative MRI and surgical management in patients with nonpalpable breast cancer: The MONET – Randomised controlled trial
April 2011 (Vol. 47 | No. 6 | Pages 879-886)
N.H.G.M. Peters, S. van Esser, M.A.A.J. van den Bosch, R.K. Storm, P.W. Plaisier, T. van Dalen, S.C.E. Diepstraten, T. Weits, P.J. Westenend, G. Stapper, M.A. Fernandez-Gallardo, I.H.M. Borel Rinkes, R. van Hillegersberg, W.P.Th.M. Mali, P.H.M. Peeters
Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment
November 2011 (Vol. 47 | No. 17 | Pages 2603-2606)
A. Becker, L. Crombag, D.A.M. Heideman, F.B. Thunnissen, A.W. van Wijk, P.E. Postmus, E.F. Smit

Most Read lists are compiled every quarter.

On the Cover

New Issue Alert

Free Trial Issue

Visit EJC Supplements

Read EJC News

EJC EUROFILE: A second chance to influence the Clinical Trials Directive

EJC INTERVIEW: Elderly breast cancer patients 'risk treatment discrimination'

New: Hormone Receptor Positive Breast Cancer Resource Centre

For all the latest research on Hormone Receptor Positive Breast Cancer, including original research articles and video interviews with leading researchers, visit our new resource centre at www.ejcancer-breast.com, edited by Professor Robert E. Coleman.

Access this journal onSciVerse ScienceDirect

EJC iPad app launch video - September 2011

EJC iPad App is now available to our readers. Download from iTunes now!

About the Journal

European Journal of Cancer is an international comprehensive oncology journal that publishes original research, editorial comments, review articles and news on experimental oncology, clinical oncology (medical, paediatric, radiation, surgical), and on cancer epidemiology and prevention.

More